← Leaderboards
David A Waltz
Children'S Hospital Boston
$84,936
Attributed
$84,936
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5K · FY2005–06$100K$75K$50K$25K$0
'05
'06
Funding mix
By agency
NIH$84,936 · 7
By mechanism
M01$84,936 · 7
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- Claudia Ordonez$792,047
- Mark Dovey$100,085
- Martha Aq Curley$18,841,267
- Cindy Norene Roy$2,211,975
- Marc N Baskin$667
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchCystic FibrosisInhalation Drug AdministrationAntibioticsClinical Trial Phase IRespiratory TherapyRespiratory Disorder ChemotherapyPatient Oriented ResearchDrug Screening /EvaluationDosageDrug Administration Rate /DurationLung DisorderClinical TrialsChildrenMicroorganism GrowthOximetryPediatricsPharmacokineticsPseudomonas AeruginosaRespiratory Disorder DiagnosisRespiratory FunctionRespiratory Infections
Grant awards (13)
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN$8,124
M01 · FY2006 · RR · contact PI
A PHASE 2 RANDOMIZED DOUBLE BLIND PARALLEL DOSE RANGING STUDY OF ORAL THERACLEC-$45,754
M01 · FY2005 · RR
24 WEEKS OF ORAL TREATMENT WITH BIIL 284 BS IN ADULT AND PEDIATRIC CF$4,358
M01 · FY2005 · RR
DURATION OF ANTIMICROBIAL TREATMENT EFFECT FOLLOWING ADMINISTRATION OF TOBI SOLU$3,632
M01 · FY2005 · RR
A MULTI-CENTER, DBL-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF INS37$726
M01 · FY2005 · RR
A Phase IA Study of Multiple Ascending Doses of Nacystelyn in CF Patients$9,868
M01 · FY2004 · RR
A Multi-Center, Dbl-Blind, Randomized, Placebo-Controlled, 28-day Study of INS37$7,075
M01 · FY2004 · RR
DURATION/EFFECT ANTIMICROBIAL TX FOLLOWING TOBRAMYCIN IN$3,351
M01 · FY2004 · RR
A Randomized, Db-Blind, Placebo-Controlled Study to Investigate The Efficacy of$2,048
M01 · FY2004 · RR
INHALED IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2002 · RR
INHALED IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
INHALED IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
INHALED IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2000 · RR